SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Morgan Stanley Maintains Overweight on NextCure, Lowers Price Target to $54

Morgan Stanley maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $58 to $54.

Benzinga · 05/08/2020 12:49

Morgan Stanley maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $58 to $54.